Literature DB >> 15036190

Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases.

Chris M Schüssler-Fiorenza1, David M Mahvi, John Niederhuber, Layton F Rikkers, Sharon M Weber.   

Abstract

Although positron emission tomography (PET) detects occult metastatic disease in approximately 20% of patients with isolated hepatic colorectal metastases, it is associated with false negative results in up to 16%. We hypothesized that patients with a poorer prognosis (as defined by clinical risk score [CRS]) would have a higher yield from PET. All patients with colorectal liver metastases who were imaged by means of PET between 1998 and 2002 were identified from a prospective PET database. All patients were assigned a CRS, with one point added for each of five preoperative factors (disease-free interval <1 year, tumor size >5 cm, tumor number >1, carcinoembryonic antigen >200, and node-positive primary lesion). A total of 85 PET scans were reviewed. In half the patients (53%), PET provided no additional information over conventional imaging. Occult extrahepatic disease was detected or questionable findings seen on conventional imaging were confirmed in 20% of PET scans, whereas PET readings were inaccurate in 27%. PET findings were correlated with CRS in a subset of 63 patients presenting with a first occurrence of hepatic colorectal metastases. Among patients with a CRS of 0, no patient had extrahepatic disease detected by PET and 57% had false positive readings, whereas among patients with a CRS of 1 or more, 14% were found to have additional disease that was detected only by PET, and there were no false positive readings (P<0.001, Fisher's exact test). Patients with isolated hepatic colorectal metastases and a CRS of 0 should undergo conventional imaging alone prior to surgical exploration.

Entities:  

Mesh:

Year:  2004        PMID: 15036190     DOI: 10.1016/j.gassur.2003.11.009

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  15 in total

1.  The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.

Authors:  K N Boykin; G B Zibari; D L Lilien; R W McMillan; D F Aultman; J C McDonald
Journal:  Am Surg       Date:  1999-12       Impact factor: 0.688

Review 2.  Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis.

Authors:  Henrik Petrowsky; Mithat Gonen; William Jarnagin; Matthias Lorenz; Ronald DeMatteo; Stefan Heinrich; Albrecht Encke; Leslie Blumgart; Yuman Fong
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

3.  Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.

Authors:  Y Fong; P F Saldinger; T Akhurst; H Macapinlac; H Yeung; R D Finn; A Cohen; N Kemeny; L H Blumgart; S M Larson
Journal:  Am J Surg       Date:  1999-10       Impact factor: 2.565

4.  Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.

Authors:  S M Strasberg; F Dehdashti; B A Siegel; J A Drebin; D Linehan
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

5.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.

Authors:  T J M Ruers; B S Langenhoff; N Neeleman; G J Jager; S Strijk; Th Wobbes; F H M Corstens; W J G Oyen
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

6.  The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.

Authors:  D T Lai; M Fulham; M S Stephen; K M Chu; M Solomon; J F Thompson; D M Sheldon; D W Storey
Journal:  Arch Surg       Date:  1996-07

7.  Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.

Authors:  B Topal; P Flamen; R Aerts; A D'Hoore; L Filez; E Van Cutsem; L Mortelmans; F Penninckx
Journal:  Eur J Surg Oncol       Date:  2001-03       Impact factor: 4.424

8.  Positron emission tomography affects surgical management in recurrent colorectal cancer patients.

Authors:  Darius C Desai; Emanuel E Zervos; Mark W Arnold; William E Burak; Joseph Mantil; Edward W Martin
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

9.  Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies.

Authors:  Thomas A D'Amico; Terence Z Wong; David H Harpole; Stephen D Brown; R Edward Coleman
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

10.  Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.

Authors:  B Nordlinger; M Guiguet; J C Vaillant; P Balladur; K Boudjema; P Bachellier; D Jaeck
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

View more
  6 in total

Review 1.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

2.  [Prognostic factors in the evaluation of colorectal liver metastases].

Authors:  T-J Song; P Adusumilli; Y Fong
Journal:  Chirurg       Date:  2005-06       Impact factor: 0.955

Review 3.  Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases.

Authors:  Yolanda Y L Yang; James W Fleshman; Steven M Strasberg
Journal:  J Gastrointest Surg       Date:  2007-07       Impact factor: 3.452

Review 4.  Role of surgery in colorectal cancer liver metastases.

Authors:  Özgür Akgül; Erdinç Çetinkaya; Şiyar Ersöz; Mesut Tez
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

5.  In colorectal liver metastases, the presence of extrahepatic disease correlates with the pathology of the primary tumour.

Authors:  Saleh Abbas; Vincent Lam
Journal:  ISRN Oncol       Date:  2011-06-22

6.  Prospective evaluation of 18F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases.

Authors:  Tim Akhurst; Mithat Gönen; Raymond E Baser; Lawrence H Schwartz; Scott Tuorto; Lynn A Brody; Anne Covey; Karen T Brown; Steven M Larson; Yuman Fong
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.